A Phase 2 interventional study of Ticagrelor Tablets and Clopidogrel (over encapsulated) capsule in Coronary Artery Disease, sponsored by AstraZeneca. Completed at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-01-13.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies testing ticagrelor in Coronary Artery Disease — 5 open to participants now, 5 under way, 2 of them phase 3. Ticagrelor · Coronary Artery Disease.
Among the 78 studies testing ticagrelor in Coronary Artery Disease, this one is the 26th largest by enrollment, is the only one that started in 2007, is one of 7 in phase 2, and was the 2nd registered.
4,863 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.
Browse Coronary Artery Disease studies →5 of the 78 studies testing ticagrelor in Coronary Artery Disease are open now, in 5 countries. Recruiting first, the newest first:
Cardiocentro Ticino · Sites in Switzerland
Ages 18+
Shiraz University of Medical Sciences · Sites in Iran, Islamic Republic of
Ages 20–80
University of Florida · Sites in United States
Ages 18+
St. Antonius Hospital · Sites in Netherlands
Ages 18+
Campus Bio-Medico University · Sites in Italy
Ages 18+
By country, each count listing its studies:
Ticagrelor: first FDA approval 2011 (BRILINTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 589 Coronary Artery Disease studies recruiting now, 403 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 12 · Phase 3 18 · Phase 4 46
First in 2006; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 123 is close to the median of 124 across 3,009 interventional studies indexed under Coronary Artery Disease.
Median enrollment 80 across the 78 interventional studies. Of the 59 that completed or were terminated, 26 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 78 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
25 studies in Coronary Artery Disease by AstraZeneca: 1 open now, 1 under way, none of them phase 3. Of 24 finished, 11 (46%) have results posted.
Among the 25 studies in Coronary Artery Disease by AstraZeneca, this one is the 10th largest by enrollment of the 22 interventional ones that give a count, is the only one that started in 2007, is one of 5 in phase 2, and was the 4th registered.
AstraZeneca’s Coronary Artery Disease studies by the year they started, since 2001.
1 of the studies testing ticagrelor in Coronary Artery Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06228456University of FloridaEffects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 78 studies testing ticagrelor in Coronary Artery Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 25 in Coronary Artery Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to see how Ticagrelor, a new oral reversible anti-platelet medication, affects platelets. Anti-platelet agents are medications that block the formation of blood clots by preventing the clumping of platelets. Blood clots prevent us from bleeding, but when they form inside the arteries their formation is linked to a risk of medical problems such as heart attack and stroke. This study investigated how long it takes for Ticagrelor to begin working and how long it takes for it to stop working after the last dose of drug. Ticagrelor will be compared to clopidogrel, an established anti-platelet treatment for preventing blood clots, and placebo plus Aspirin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Aspirin + Placebo
Drug: Aspirin Tablets
Aspirin + clopidogrel
Drug: Clopidogrel (over encapsulated) capsule · Drug: Aspirin Tablets
Aspirin + Ticagrelor
Drug: Ticagrelor Tablets · Drug: Aspirin Tablets
Oral, 90 mg; 180 mg loading dose followed by 90 mg twice daily (BD)
Oral 75 mg; 600 mg loading dose followed by 75 mg once daily (ODD)
Also known as: Plavix, Clopidogrel Bisulfate
Oral, 75 mg to 100 mg once daily. Aspirin obtained locally by the investigator, according to local practice. The dose remained constant throughout the study.
Also known as: ASA
Final Extent Inhibition of Platelet Aggregation (IPA) Induced by 20 µM Adenosine Diphosphate (ADP) at 2 Hours After First Dose
IPA(%)=(PAb-PAt)/PAb\*100.The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.
Time frame: At 2 hours after first dose of study drug
Slope of Extent IPA Offset Curve 4 to 72 Hours After Last Dose of Study Drug
IPA(%)=(PAb-PAt)/PAb\*100.The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. The unit for the slope of IPA curve is percent/hour.
Time frame: 4 to 72 Hours after last dose of study drug
Final Extent IPA Induced by 20 µM ADP at 0.5 Hours After First Dose
IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.
Time frame: 0.5 hours after first dose
Final Extent IPA Induced by 20 µM ADP at 1 Hour After First Dose
IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.
Time frame: 1 hour after first dose
Final Extent IPA Induced by 20 µM ADP at 4 Hours After First Dose
IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.
Time frame: 4 hours after first dose
Final Extent IPA Induced by 20 µM ADP at 8 Hours After First Dose
IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.
Time frame: 8 hours after first dose
Final Extent IPA Induced by 20 µM ADP at 24 Hours After First Dose
IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.
Time frame: 24 hours after first dose
Final Extent IPA Induced by 20 µM ADP at 0 Hour Before Last Dose
IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.
Time frame: 0 hour before last dose
Final Extent IPA Induced by 20 µM ADP at 2 Hours After Last Dose
IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.
Time frame: 2 hours after last dose
Final Extent IPA Induced by 20 µM ADP at 4 Hours After Last Dose
IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.
Time frame: 4 hours after last dose
Final Extent IPA Induced by 20 µM ADP at 8 Hours After Last Dose
IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.
Time frame: 8 hours after last dose
Final Extent IPA Induced by 20 µM ADP at 24 Hours After Last Dose
IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.
Time frame: 24 hours after last dose
Final Extent IPA Induced by 20 µM ADP at 48 Hours After Last Dose
IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.
Time frame: 48 hours after last dose
Final Extent IPA Induced by 20 µM ADP at 72 Hours After Last Dose
IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.
Time frame: 72 hours after last dose
Final Extent IPA Induced by 20 µM ADP at 120 Hours - Day 5 After Last Dose
IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.
Time frame: 120 hours - Day 5 after last dose
Final Extent IPA Induced by 20 µM ADP at 168 Hours - Day 7 After Last Dose
IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference of baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.
Time frame: 168 hours - Day 7 after last dose
Final Extent IPA Induced by 20 µM ADP at 240 Hours - Day 10 After Last Dose
IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.
Time frame: 240 hours - Day 10 after last dose
Cardiopulmonary Parameters at Baseline: Forced Expiratory Volume in 1 Second (FEV1)
FEV1 is measured by Spirometry, the unit is Liter.
Time frame: Baseline
Cardiopulmonary Parameters at Post 6-week Treatment: FEV1
FEV1 is measured by Spirometry, the unit is Liter.
Time frame: 6-week post treatment
Cardiopulmonary Parameters at Baseline: Forced Vital Capacity (FVC)
FVC is measured by Spirometry, the unit is Liter.
Time frame: Baseline
Cardiopulmonary Parameters at Post 6-week Treatment: FVC
FVC is measured by Spirometry, the unit is Liter.
Time frame: 6-week post treatment
Cardiopulmonary Parameters at Baseline: Ratio of Forced Expiratory Volume in 1 Second Over Forced Vital Capacity (FEV1/FVC Ratio)
FEV1/FVC Ratio is measured by Spirometry, the unit is Ratio.
Time frame: Baseline
Cardiopulmonary Parameters at Post 6-week Treatment: FEV1/FVC Ratio
FEV1/FVC Ratio is measured by Spirometry, the unit is Ratio.
Time frame: 6-week post treatment
Cardiopulmonary Parameters at Baseline: Mean Forced Expiratory Flow Between 25% and 75% of the FVC (FEF25-75)
FEF25-75 is measured by Spirometry, the unit is Liter/Second.
Time frame: Baseline
Cardiopulmonary Parameters Post 6-week Treatment: FEF25-75
FEF25-75 is measured by Spirometry, the unit is Liter/Second.
Time frame: 6-week post treatment
Cardiopulmonary Parameters at Baseline: Functional Residual Capacity (FRC)
FRC is measured by Body Box Plethysmography, the unit is Liter.
Time frame: Baseline
Cardiopulmonary Parameters Post 6-week Treatment: FRC
FRC is measured by Body Box Plethysmography, the unit is Liter.
Time frame: 6-week post treatment
Cardiopulmonary Parameters at Baseline: Total Lung Capacity (TLC)
TLC is measured by Body Box Plethysmography, the unit is Liter.
Time frame: Baseline
Cardiopulmonary Parameters Post 6-week Treatment: TLC
TLC is measured by Body Box Plethysmography, the unit is Liter.
Time frame: 6-week post treatment
Cardiopulmonary Parameters at Baseline: Residual Volume (RV)
RV is measured by Body Box Plethysmography, the unit is Liter.
Time frame: Baseline
Cardiopulmonary Parameters Post 6-week Treatment: RV
RV is measured by Body Box Plethysmography, the unit is Liter.
Time frame: 6-week post treatment
Cardiopulmonary Parameters at Baseline: Minute Ventilation (VE)
VE is measured by Spirometry and Body Box Plethysmography, the unit is Liter/Minute
Time frame: Baseline
Cardiopulmonary Parameters Post 6-week Treatment: VE
VE is measured by Spirometry and Body Box Plethysmography, the unit is Liter/Minute
Time frame: 6-week post treatment
Cardiopulmonary Parameters at Baseline: Respiratory Rate (RR)
RR is measured by Spirometry and Body Box Plethysmography, the unit is Breaths/Minute.
Time frame: Baseline
Cardiopulmonary Parameters Post 6-week Treatment: RR
RR is measured by Spirometry and Body Box Plethysmography, the unit is Breaths/Minute.
Time frame: 6-week post treatment
Cardiopulmonary Parameters at Baseline: Tidal Volume (VT)
VT is measured by Body Box Plethysmography, the unit is Liter/Minute.
Time frame: Baseline
Cardiopulmonary Parameters Post 6-week Treatment: VT
VT is measured by Body Box Plethysmography, the unit is Liter/Minute.
Time frame: 6-week post treatment
Cardiopulmonary Parameters at Baseline: Single Breath Diffusing Capacity for the Lungs Using Carbon Monoxide (DLCOSB)
DLCOSB is measured by Body Box Plethysmography, the unit is Percent.
Time frame: Baseline
Cardiopulmonary Parameters Post 6-week Treatment: DLCOSB
DLCOSB is measured by Body Box Plethysmography, the unit is Percent.
Time frame: 6-week post treatment
Cardiopulmonary Parameters at Baseline: Ejection Fraction (EF)
EF is measured by Echocardiogram, the unit is Percent. The ejection fraction is defined by: (LV diastolic volume - LV systolic volume)/LV diastolic volume. The unit % is the percentage change of left ventricular diastolic versus systolic volume relative to the diastolic volume. LV is the left ventricle.
Time frame: Baseline
Cardiopulmonary Parameters Post 6-week Treatment: EF
EF is measured by Echocardiogram, the unit is Percent. The ejection fraction is defined by: (LV diastolic volume - LV systolic volume)/LV diastolic volume. The unit % is the percentage change of left ventricular diastolic versus systolic volume relative to the diastolic volume. LV is the left ventricle.
Time frame: 6-week post treatment
Cardiopulmonary Parameters at Baseline: N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
NT-proBNP is measured by clinical lab, the unit is pg/mL.
Time frame: Baseline
Cardiopulmonary Parameters Post 6-week Treatment: NT-proBNP
NT-proBNP is measured by clinical lab, the unit is pg/mL.
Time frame: 6-week post treatment
Cardiopulmonary Parameters at Baseline: Blood Oxygen Saturation Measured by Pulse Oximetry (SpO2)
SpO2 is measured by pulse oximetry, the unit is Percent. The unit % is the percentage of oxygen attached hemoglobin relative to the total hemoglobin.
Time frame: Baseline
Cardiopulmonary Parameters Post 6-week Treatment: SpO2
SpO2 is measured by pulse oximetry, the unit is Percent. The unit % is the percentage of oxygen attached hemoglobin relative to the total hemoglobin.
Time frame: 6-week post treatment
| Milestone | Ticagrelor | Clopidogrel | Placebo |
|---|---|---|---|
| Started | 57 | 54 | 12 |
| Completed | 52 | 51 | 11 |
| Not completed | 5 | 3 | 1 |
| Withdrew: Adverse event | 4 | 0 | 1 |
| Withdrew: Incorrect enrolment | 1 | 1 | 0 |
| Withdrew: Severe non-compliance to protocol | 0 | 1 | 0 |
| Withdrew: Prior commitment medication | 0 | 1 | 0 |
IPA(%)=(PAb-PAt)/PAb\*100.The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.
| Percentage | Ticagrelor | Clopidogrel |
|---|---|---|
| Final Extent Inhibition of Platelet Aggregation (IPA) Induced by 20 µM Adenosine Diphosphate (ADP) at 2 Hours After First Dose | 93.15 (80.4 to 100.0) | 31.05 (10.3 to 56.9) |
IPA(%)=(PAb-PAt)/PAb\*100.The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. The unit for the slope of IPA curve is percent/hour.
| Percentage/Hour | Ticagrelor | Clopidogrel |
|---|---|---|
| Slope of Extent IPA Offset Curve 4 to 72 Hours After Last Dose of Study Drug | -1.037 ± 0.076 | -0.482 ± 0.055 |
IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.
| Percentage | Ticagrelor | Clopidogrel |
|---|---|---|
| Final Extent IPA Induced by 20 µM ADP at 0.5 Hours After First Dose | 45.39 (3.0 to 66.4) | 4.71 (0.0 to 14.8) |
IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.
| Percentage | Ticagrelor | Clopidogrel |
|---|---|---|
| Final Extent IPA Induced by 20 µM ADP at 1 Hour After First Dose | 86.71 (72.6 to 99.4) | 15.83 (0.0 to 32.5) |
IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.
| Percentage | Ticagrelor | Clopidogrel |
|---|---|---|
| Final Extent IPA Induced by 20 µM ADP at 4 Hours After First Dose | 98.39 (84.2 to 100.0) | 40.87 (16.6 to 69.3) |
IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.
| Percentage | Ticagrelor | Clopidogrel |
|---|---|---|
| Final Extent IPA Induced by 20 µM ADP at 8 Hours After First Dose | 96.99 (81.1 to 100.0) | 46.90 (20.4 to 80.8) |
IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.
| Percentage | Ticagrelor | Clopidogrel |
|---|---|---|
| Final Extent IPA Induced by 20 µM ADP at 24 Hours After First Dose | 87.29 (62.9 to 98.4) | 49.64 (17.7 to 76.9) |
IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.
| Percentage | Ticagrelor | Clopidogrel |
|---|---|---|
| Final Extent IPA Induced by 20 µM ADP at 0 Hour Before Last Dose | 74.53 (56.5 to 98.3) | 51.75 (32.8 to 66.4) |
IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.
| Percentage | Ticagrelor | Clopidogrel |
|---|---|---|
| Final Extent IPA Induced by 20 µM ADP at 2 Hours After Last Dose | 91.49 (83.0 to 100.0) | 62.96 (35.2 to 78.8) |
IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.
| Percentage | Ticagrelor | Clopidogrel |
|---|---|---|
| Final Extent IPA Induced by 20 µM ADP at 4 Hours After Last Dose | 96.10 (80.4 to 100.0) | 61.80 (35.2 to 88.4) |
IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.
| Percentage | Ticagrelor | Clopidogrel |
|---|---|---|
| Final Extent IPA Induced by 20 µM ADP at 8 Hours After Last Dose | 88.31 (77.3 to 100.0) | 61.31 (39.0 to 61.31) |
IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.
| Percentage | Ticagrelor | Clopidogrel |
|---|---|---|
| Final Extent IPA Induced by 20 µM ADP at 24 Hours After Last Dose | 55.18 (39.1 to 85.4) | 53.91 (35.1 to 73.3) |
IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.
| Percentage | Ticagrelor | Clopidogrel |
|---|---|---|
| Final Extent IPA Induced by 20 µM ADP at 48 Hours After Last Dose | 30.94 (14.3 to 51.5) | 45.79 (19.4 to 54.7) |
IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.
| Percentage | Ticagrelor | Clopidogrel |
|---|---|---|
| Final Extent IPA Induced by 20 µM ADP at 72 Hours After Last Dose | 11.76 (0.0 to 34.5) | 21.09 (10.2 to 47.6) |
IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.
| Percentage | Ticagrelor | Clopidogrel |
|---|---|---|
| Final Extent IPA Induced by 20 µM ADP at 120 Hours - Day 5 After Last Dose | 0.0 (0.0 to 15.2) | 21.15 (0.0 to 34.7) |
IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference of baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.
| Percentage | Ticagrelor | Clopidogrel |
|---|---|---|
| Final Extent IPA Induced by 20 µM ADP at 168 Hours - Day 7 After Last Dose | 0.0 (0.0 to 11.7) | 6.32 (0.0 to 22.4) |
IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.
| Percentage | Ticagrelor | Clopidogrel |
|---|---|---|
| Final Extent IPA Induced by 20 µM ADP at 240 Hours - Day 10 After Last Dose | 1.64 (0.0 to 9.9) | 0.98 (0.0 to 13.8) |
FEV1 is measured by Spirometry, the unit is Liter.
| Liter | Ticagrelor | Clopidogrel | Placebo |
|---|---|---|---|
| Cardiopulmonary Parameters at Baseline: Forced Expiratory Volume in 1 Second (FEV1) | 2.79 ± 0.725 | 2.71 ± 0.791 | 2.94 ± 0.654 |
FEV1 is measured by Spirometry, the unit is Liter.
| Liter | Ticagrelor | Clopidogrel | Placebo |
|---|---|---|---|
| Cardiopulmonary Parameters at Post 6-week Treatment: FEV1 | 2.77 ± 0.712 | 2.74 ± 0.751 | 2.95 ± 0.727 |
FVC is measured by Spirometry, the unit is Liter.
| Liter | Ticagrelor | Clopidogrel | Placebo |
|---|---|---|---|
| Cardiopulmonary Parameters at Baseline: Forced Vital Capacity (FVC) | 3.72 ± 0.903 | 3.73 ± 1.082 | 4.03 ± 0.858 |
FVC is measured by Spirometry, the unit is Liter.
| Liter | Ticagrelor | Clopidogrel | Placebo |
|---|---|---|---|
| Cardiopulmonary Parameters at Post 6-week Treatment: FVC | 3.70 ± 0.933 | 3.78 ± 1.029 | 3.98 ± 0.890 |
FEV1/FVC Ratio is measured by Spirometry, the unit is Ratio.
| Ratio | Ticagrelor | Clopidogrel | Placebo |
|---|---|---|---|
| Cardiopulmonary Parameters at Baseline: Ratio of Forced Expiratory Volume in 1 Second Over Forced Vital Capacity (FEV1/FVC Ratio) | 75.01 ± 7.049 | 73.04 ± 6.764 | 73.13 ± 7.226 |
FEV1/FVC Ratio is measured by Spirometry, the unit is Ratio.
| Ratio | Ticagrelor | Clopidogrel | Placebo |
|---|---|---|---|
| Cardiopulmonary Parameters at Post 6-week Treatment: FEV1/FVC Ratio | 74.71 ± 5.694 | 72.84 ± 6.371 | 74.27 ± 7.836 |
FEF25-75 is measured by Spirometry, the unit is Liter/Second.
| Liter/second | Ticagrelor | Clopidogrel | Placebo |
|---|---|---|---|
| Cardiopulmonary Parameters at Baseline: Mean Forced Expiratory Flow Between 25% and 75% of the FVC (FEF25-75) | 2.88 ± 1.251 | 2.70 ± 1.208 | 2.50 ± 1.243 |
FEF25-75 is measured by Spirometry, the unit is Liter/Second.
| Liter/second | Ticagrelor | Clopidogrel | Placebo |
|---|---|---|---|
| Cardiopulmonary Parameters Post 6-week Treatment: FEF25-75 | 2.77 ± 1.289 | 2.67 ± 1.156 | 2.91 ± 1.375 |
FRC is measured by Body Box Plethysmography, the unit is Liter.
| Liter | Ticagrelor | Clopidogrel | Placebo |
|---|---|---|---|
| Cardiopulmonary Parameters at Baseline: Functional Residual Capacity (FRC) | 2.79 ± 0.827 | 2.89 ± 0.876 | 2.91 ± 0.679 |
FRC is measured by Body Box Plethysmography, the unit is Liter.
| Liter | Ticagrelor | Clopidogrel | Placebo |
|---|---|---|---|
| Cardiopulmonary Parameters Post 6-week Treatment: FRC | 2.73 ± 0.723 | 2.79 ± 0.857 | 2.75 ± 1.000 |
TLC is measured by Body Box Plethysmography, the unit is Liter.
| Liter | Ticagrelor | Clopidogrel | Placebo |
|---|---|---|---|
| Cardiopulmonary Parameters at Baseline: Total Lung Capacity (TLC) | 5.78 ± 1.299 | 5.83 ± 1.401 | 6.10 ± 1.037 |
TLC is measured by Body Box Plethysmography, the unit is Liter.
| Liter | Ticagrelor | Clopidogrel | Placebo |
|---|---|---|---|
| Cardiopulmonary Parameters Post 6-week Treatment: TLC | 5.70 ± 1.182 | 5.85 ± 1.396 | 5.96 ± 1.422 |
RV is measured by Body Box Plethysmography, the unit is Liter.
| Liter | Ticagrelor | Clopidogrel | Placebo |
|---|---|---|---|
| Cardiopulmonary Parameters at Baseline: Residual Volume (RV) | 1.94 ± 0.780 | 2.01 ± 0.643 | 1.91 ± 0.363 |
RV is measured by Body Box Plethysmography, the unit is Liter.
| Liter | Ticagrelor | Clopidogrel | Placebo |
|---|---|---|---|
| Cardiopulmonary Parameters Post 6-week Treatment: RV | 1.88 ± 0.621 | 1.97 ± 0.559 | 1.90 ± 0.751 |
VE is measured by Spirometry and Body Box Plethysmography, the unit is Liter/Minute
| Liter/minute | Ticagrelor | Clopidogrel | Placebo |
|---|---|---|---|
| Cardiopulmonary Parameters at Baseline: Minute Ventilation (VE) | 12.92 ± 3.950 | 12.17 ± 3.552 | 12.06 ± 4.054 |
VE is measured by Spirometry and Body Box Plethysmography, the unit is Liter/Minute
| Liter/minute | Ticagrelor | Clopidogrel | Placebo |
|---|---|---|---|
| Cardiopulmonary Parameters Post 6-week Treatment: VE | 13.69 ± 3.582 | 13.14 ± 5.515 | 11.45 ± 3.540 |
RR is measured by Spirometry and Body Box Plethysmography, the unit is Breaths/Minute.
| Breaths/minute | Ticagrelor | Clopidogrel | Placebo |
|---|---|---|---|
| Cardiopulmonary Parameters at Baseline: Respiratory Rate (RR) | 14.79 ± 2.433 | 14.15 ± 2.743 | 15.5 ± 1.977 |
RR is measured by Spirometry and Body Box Plethysmography, the unit is Breaths/Minute.
| Breaths/minute | Ticagrelor | Clopidogrel | Placebo |
|---|---|---|---|
| Cardiopulmonary Parameters Post 6-week Treatment: RR | 15.21 ± 2.817 | 15.10 ± 2.303 | 14.91 ± 0.944 |
VT is measured by Body Box Plethysmography, the unit is Liter/Minute.
| Liters/minute | Ticagrelor | Clopidogrel | Placebo |
|---|---|---|---|
| Cardiopulmonary Parameters at Baseline: Tidal Volume (VT) | 0.96 ± 0.326 | 0.89 ± 0.322 | 0.89 ± 0.273 |
VT is measured by Body Box Plethysmography, the unit is Liter/Minute.
| Liters/minute | Ticagrelor | Clopidogrel | Placebo |
|---|---|---|---|
| Cardiopulmonary Parameters Post 6-week Treatment: VT | 0.92 ± 0.264 | 0.93 ± 0.393 | 0.83 ± 0.329 |
DLCOSB is measured by Body Box Plethysmography, the unit is Percent.
| Percent | Ticagrelor | Clopidogrel | Placebo |
|---|---|---|---|
| Cardiopulmonary Parameters at Baseline: Single Breath Diffusing Capacity for the Lungs Using Carbon Monoxide (DLCOSB) | 17.00 ± 8.673 | 17.29 ± 10.891 | 15.83 ± 6.013 |
DLCOSB is measured by Body Box Plethysmography, the unit is Percent.
| Percent | Ticagrelor | Clopidogrel | Placebo |
|---|---|---|---|
| Cardiopulmonary Parameters Post 6-week Treatment: DLCOSB | 16.38 ± 8.090 | 16.53 ± 8.286 | 16.09 ± 7.190 |
EF is measured by Echocardiogram, the unit is Percent. The ejection fraction is defined by: (LV diastolic volume - LV systolic volume)/LV diastolic volume. The unit % is the percentage change of left ventricular diastolic versus systolic volume relative to the diastolic volume. LV is the left ventricle.
| Percent | Ticagrelor | Clopidogrel | Placebo |
|---|---|---|---|
| Cardiopulmonary Parameters at Baseline: Ejection Fraction (EF) | 57.96 ± 9.302 | 61.91 ± 7.624 | 59.92 ± 10.013 |
EF is measured by Echocardiogram, the unit is Percent. The ejection fraction is defined by: (LV diastolic volume - LV systolic volume)/LV diastolic volume. The unit % is the percentage change of left ventricular diastolic versus systolic volume relative to the diastolic volume. LV is the left ventricle.
| Percent | Ticagrelor | Clopidogrel | Placebo |
|---|---|---|---|
| Cardiopulmonary Parameters Post 6-week Treatment: EF | 60.70 ± 8.430 | 62.38 ± 7.096 | 60.73 ± 9.665 |
NT-proBNP is measured by clinical lab, the unit is pg/mL.
| pg/ml | Ticagrelor | Clopidogrel | Placebo |
|---|---|---|---|
| Cardiopulmonary Parameters at Baseline: N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) | 163.34 ± 184.298 | 185.98 ± 227.141 | 145.41 ± 144.522 |
NT-proBNP is measured by clinical lab, the unit is pg/mL.
| pg/ml | Ticagrelor | Clopidogrel | Placebo |
|---|---|---|---|
| Cardiopulmonary Parameters Post 6-week Treatment: NT-proBNP | 139.88 ± 170.347 | 214.43 ± 313.429 | 140.68 ± 145.003 |
SpO2 is measured by pulse oximetry, the unit is Percent. The unit % is the percentage of oxygen attached hemoglobin relative to the total hemoglobin.
| Percent | Ticagrelor | Clopidogrel | Placebo |
|---|---|---|---|
| Cardiopulmonary Parameters at Baseline: Blood Oxygen Saturation Measured by Pulse Oximetry (SpO2) | 96.59 ± 1.570 | 96.78 ± 1.949 | 97.58 ± 1.240 |
SpO2 is measured by pulse oximetry, the unit is Percent. The unit % is the percentage of oxygen attached hemoglobin relative to the total hemoglobin.
| Percentage | Ticagrelor | Clopidogrel | Placebo |
|---|---|---|---|
| Cardiopulmonary Parameters Post 6-week Treatment: SpO2 | 97.73 ± 1.239 | 97.35 ± 1.262 | 98.56 ± 1.014 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ticagrelor | — | 0/57 (0%) | 36/57 (63.2%) |
| Clopidogrel | — | 0/54 (0%) | 22/54 (40.7%) |
| Placebo | — | 0/12 (0%) | 7/12 (58.3%) |
| Event | Ticagrelor | Clopidogrel | Placebo |
|---|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 20/57 | 6/54 | 0/12 |
| Increased Tendency To BruiseSkin and subcutaneous tissue disorders | 9/57 | 2/54 | 0/12 |
| ContusionInjury, poisoning and procedural complications | 6/57 | 3/54 | 0/12 |
| Vessel Puncture Site HaematomaGeneral disorders | 3/57 | 5/54 | 1/12 |
| Visual ImpairmentEye disorders | 0/57 | 0/54 | 1/12 |
| DyspepsiaGastrointestinal disorders | 2/57 | 0/54 | 1/12 |
| Abdominal Wall HaematomaGastrointestinal disorders | 0/57 | 0/54 | 1/12 |
| FatigueGeneral disorders | 4/57 | 2/54 | 1/12 |
| Chest DiscomfortGeneral disorders | 1/57 | 0/54 | 1/12 |
| CellulitisInfections and infestations | 0/57 | 0/54 | 1/12 |
| Age Continuous(Year) | Ticagrelor | Clopidogrel | Placebo | Total |
|---|---|---|---|---|
| Mean | 62.2 ± 9.10 | 65.4 ± 7.98 | 63.9 ± 8.32 | 63.8 ± 8.62 |
| Sex: Female, Male(Participants) | Ticagrelor | Clopidogrel | Placebo | Total |
|---|---|---|---|---|
| Female | 14 | 14 | 2 | 30 |
| Male | 43 | 40 | 10 | 93 |
The record gives a start of Oct 2007, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2012, 2 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ticagrelor